% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

  • pivalde pivalde Jan 31, 2013 1:16 AM Flag

    8.8 M left

    Prana reports that 31st of Jan it had 8.8 M left and it had used 4.5M in the first half year. So there will be need for new cash latest after the HD results.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Does anyone feel that Prana management could show that they have more than just dilution in their playbook. When I read about the synergistic effects of PBT519 with temozolomide, and that temozolomide simply is not effective in some people. It seems that Prana could come to some mutually beneficial financial arrangement with Sigma-Aldrich that would help to assure market dominance but sharing in the development and spoils of PBT519. With a growing pipeline should come an expanded playbook. It just seems to jump out as a viable opportunity for partnering, that could propel Prana into a new league as a company.

      You see a lot of baseball games won by a bunt or sacrifice fly. I can support a go-it-alone approach on their most promising drugs to capture the biggest ROI, but with a growing pipeline it should not be their only course at this stage as a company. They should really strive to put themselves on the map. It is my estimation that currently PBT519 adds zero to their current shareprice, so a deal on PBT519 could be like hitting a homerun with 2 players on base.

      Brain Cancer. In September 2009, we received a report on a study conducted on PBT519, our lead brain cancer MPAC, by the Royal Melbourne Hospital. The report showed that PBT519 was able to significantly prevent the growth of the tumors of the deadly glioblastoma multiforme form of brain cancer in mouse models of the disease. Moreover, PBT519 appeared to be very well tolerated and was at least as efficacious as the current leading form of chemotherapy, temozolomide. The data indicates that PBT519 may work synergistically with temozolomide in reducing the growth of such brain tumors. The company is generating mechanistic information on the behaviour of this compound and generating other structurally related MPACs with potential anti -cancer activity. During 2012, prospective candidate compounds have been submitted to the National Institutes for Cancer in the National Institutes of Health and the Department of Health and Human Services based in Bethesda, Maryland. See Item 4.B “Business Overview – Platform Technology and Research Programs – Brain Cancer.”

0.505-0.0050(-0.98%)Feb 12 3:54 PMEST